TY - JOUR
T1 - The role of aldosterone receptor antagonists in the management of heart failure
T2 - An update
AU - Nagarajan, Vijaiganesh
AU - Chamsi-Pasha, Mohammed
AU - Tang, W. H.Wilson
PY - 2012/9
Y1 - 2012/9
N2 - The aldosterone receptor antagonists (ARAs) spironolactone (Aldactone) and eplerenone (Inspra) have become part of standard medical therapy for heart failure, having shown clinical efficacy in randomized trials in patients with advanced symptomatic systolic heart failure, postinfarction heart failure with cardiac dysfunction, and systolic heart failure with mild symptoms. The benefits include a lower rate of death. Yet to be answered is whether the two drugs are clinically equivalent; another question is whether they may benefit everyone with symptomatic heart failure, including diastolic heart failure.
AB - The aldosterone receptor antagonists (ARAs) spironolactone (Aldactone) and eplerenone (Inspra) have become part of standard medical therapy for heart failure, having shown clinical efficacy in randomized trials in patients with advanced symptomatic systolic heart failure, postinfarction heart failure with cardiac dysfunction, and systolic heart failure with mild symptoms. The benefits include a lower rate of death. Yet to be answered is whether the two drugs are clinically equivalent; another question is whether they may benefit everyone with symptomatic heart failure, including diastolic heart failure.
UR - http://www.scopus.com/inward/record.url?scp=84867168350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867168350&partnerID=8YFLogxK
U2 - 10.3949/ccjm.79a.12014
DO - 10.3949/ccjm.79a.12014
M3 - Review article
C2 - 22949344
AN - SCOPUS:84867168350
SN - 0891-1150
VL - 79
SP - 631
EP - 639
JO - Cleveland Clinic journal of medicine
JF - Cleveland Clinic journal of medicine
IS - 9
ER -